BackTable Vascular & Interventional Ep. 556 Dosimetry University IV: Optimizing Radiation Segmentectomy with Dr. Nima Kokabi and Dr. Tyler Sandow
7 snips
Jul 8, 2025 Join interventional oncologists Dr. Nima Kokabi, an expert in Y90 treatment strategies, and Dr. Tyler Sandow as they dive into the nuances of radiation segmentectomy. They uncover the curative potential of Y90 compared to traditional methods, emphasizing the importance of achieving complete pathological necrosis for better survival rates. The duo discusses personalized approaches for treating metastatic liver cancers, explores complex case studies, and examines the critical role of advanced imaging and dosimetry in enhancing patient outcomes.
AI Snips
Chapters
Transcript
Episode notes
Ablative Y90 Is Curative
- Ablative Y90 can be curative with overall survival comparable to resection or transplant in liver cancer.
- Achieving complete pathological necrosis (CPN) correlates strongly with durable tumor response.
Choose Therapy By Confidence
- Choose the local regional therapy (Y90 or ablation) that gives you the most confidence in achieving complete pathological necrosis.
- Personalize treatment choice based on expertise and patient factors for best tumor control.
CPN Rates Differ by Center
- Community centers have lower complete pathological necrosis (CPN) rates with Y90 than major academic centers.
- UNOS data show CPN rates of 20% for TACE vs. 35% to 40% for Y90 and ablation across all centers.